There is accumulating evidence that retinal microglia are indeed associated with diabetic retinopathy. Minocycline is a second-generation tetracycline, which has anti-inflammatory properties that are separate from its anti-microbial properties. The study objective is to investigate the safety and efficacy of minocycline, a microglia inhibitor, in the treatment of diabetic macular edema. This is a prospective, non-randomized, uncontrolled, single group, single center pilot study to investigate the safety and efficacy of minocycline as a microglia inhibitor in patients with DME who have already been treated with standard-of-care laser or who are not amenable to standard-of-care therapy. The study has ended but we continue to analyze the data.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAEY000499-06
Application #
9155595
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2015
Total Cost
Indirect Cost
Name
U.S. National Eye Institute
Department
Type
DUNS #
City
State
Country
Zip Code
Cukras, Catherine A; Petrou, Philip; Chew, Emily Y et al. (2012) Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest Ophthalmol Vis Sci 53:3865-74